Neurology Search
Neurology Neurology
parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia
PARKINSON'S DISEASE & PARKINSON'S DISEASE DEMENTIA

Parkinson's disease is a progressive neurodegenerative disorder that is common, age-related and chronic.

It is caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain.

Onset of symptoms and progression of the disease is gradual.

Motor signs and symptoms include resting tremor, rigidity, bradykinesia and postural instability.

Parkinson's disease dementia indicates loss of intellectual functions including memory, significant deterioration in the ability to carry out day-to-day activities and changes in social behavior are often noted.

Parkinson's Disease & Parkinson's Disease Dementia Drug Information

Drug Information

Indication: Patients w/ moderate to severe Alzheimer's disease.

Indication: Parkinson's disease either as monotherapy or combined w/ dopatherapy from the outset or secondarily.

Indication: Mild, moderate & severe Alzheimer's dementia.

Indication: Parkinson's disease. Menstrual disorders & infertility. Benign breast disease. Prolactinoma. Acromegaly.

Indication: Signs & symptoms of advanced idiopathic Parkinson's disease as monotherapy or in combination w/ levodopa. ...

Indication: Signs & symptoms of advanced idiopathic Parkinson's disease as monotherapy or in combination w/ levodopa.

Indication: Relief of muscular conditions, tension headache, non-articular rheumatism & dysmenorrhoea.

Indication: Mild, moderate & severe Alzheimer's dementia.

Indication: Adjunct to l-dopa/benserazide or l-dopa/carbidopa in patients w/ Parkinson's disease & end-of-dose motor f...

Indication: Mild to moderately severe dementia associated w/ Alzheimer's or Parkinson's disease & severe dementia asso...

1  /  4
1  /  4
Editor's Recommendations
Most Read Articles
Migraine a risk factor for dementia?
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Fremanezumab: Sustained benefits across the board for refractory migraine
Pearl Toh, 03 Jul 2020
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
Aducanumab in Alzheimer’s disease: Does it work?
Pearl Toh, 24 Jun 2020
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Active lifestyle may delay Alzheimer’s disease progression
Roshini Claire Anthony, 13 Aug 2019

An active lifestyle, regardless of vascular risk, may delay the progression of Alzheimer’s disease (AD) by slowing down cognitive decline and neurodegeneration, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).